ZX-8177 / Zenshine Pharmaceuticals - LARVOL DELTA

Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Recruiting | Sponsor: Nanjing Zenshine Pharmaceuticals | Not yet recruiting ➔ Recruiting

Enrollment open • Solid Tumor

Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of ZX-8177 in Patients With Advanced Solid Tumors (clinicaltrials.gov) - P1 | N=80 | Not yet recruiting | Sponsor: Nanjing Zenshine Pharmaceuticals

New P1 trial • Solid Tumor

ENPP1 inhibitor ZX-8177 in combination with chemotherapy or radiation exhibits synergistic anti-tumor effects via STING-mediated response (AACR 2023) - "Synergistic anti-tumor efficacy was observed in CT-26 model with the combination of Mitomycin C (0.5 mg/kg, BIW) and ZX-8177 (25 mg/kg, oral, BID), and in 4T1 and Pan02 models with the combination of Cisplatin (5 mg/kg, BIW) and ZX-8177 (25 mg/kg, oral, BID). Currently, ZX-8177 is under IND-enabling pre-clinical evaluation. First-in-human study of ZX-8177 is in planning as a single agent and combination therapies."

Combination therapy • Oncology • CD8 • CXCL10 • GZMA • GZMB • IFNB1 • STING